Acuta Capital Partners LLC bought a new stake in Geron Co. (NASDAQ:GERN - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 154,900 shares of the biopharmaceutical company's stock, valued at approximately $703,000.
Several other hedge funds and other institutional investors have also modified their holdings of GERN. National Bank of Canada FI boosted its position in Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 6,000 shares during the period. American Trust purchased a new stake in Geron in the 1st quarter worth approximately $38,000. Rovin Capital UT ADV acquired a new stake in shares of Geron during the 3rd quarter valued at $62,000. CIBC Asset Management Inc grew its holdings in shares of Geron by 32.7% during the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 3,805 shares in the last quarter. Finally, Csenge Advisory Group acquired a new position in shares of Geron in the second quarter worth $66,000. Institutional investors and hedge funds own 73.71% of the company's stock.
Geron Price Performance
NASDAQ:GERN traded up $0.11 during mid-day trading on Thursday, reaching $4.17. 6,472,425 shares of the company were exchanged, compared to its average volume of 10,377,381. Geron Co. has a 12 month low of $1.64 and a 12 month high of $5.34. The company has a fifty day moving average of $4.19 and a 200 day moving average of $4.32. The stock has a market cap of $2.52 billion, a PE ratio of -13.03 and a beta of 0.52. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.
Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. The firm had revenue of $28.27 million for the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business's revenue for the quarter was up 17138.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.08) EPS. On average, research analysts anticipate that Geron Co. will post -0.25 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Wedbush restated an "outperform" rating and issued a $8.00 target price on shares of Geron in a research note on Thursday, August 8th. HC Wainwright started coverage on shares of Geron in a research note on Tuesday, November 5th. They issued a "buy" rating and a $8.00 target price for the company. Leerink Partnrs raised Geron to a "strong-buy" rating in a research note on Monday, September 9th. StockNews.com upgraded shares of Geron to a "sell" rating in a research note on Monday, August 5th. Finally, Scotiabank started coverage on shares of Geron in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.05.
View Our Latest Stock Analysis on Geron
Geron Company Profile
(
Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.